AxoGen Inc. (NASDAQ:AXGN)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a research note issued on Friday. They presently have a $12.00 target price on the stock. Wedbush’s price objective points to a potential upside of 36.36% from the stock’s current price.
AXGN has been the subject of a number of other research reports. Lake Street Capital cut shares of AxoGen from a “buy” rating to a “hold” rating and set a $9.00 target price for the company. in a research report on Thursday, November 3rd. JMP Securities reiterated a “buy” rating on shares of AxoGen in a research report on Tuesday, November 22nd.
Shares of AxoGen (NASDAQ:AXGN) opened at 8.45 on Friday. The company’s 50-day moving average is $8.66 and its 200 day moving average is $7.71. The firm’s market capitalization is $277.99 million. AxoGen has a 1-year low of $4.52 and a 1-year high of $9.88.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). AxoGen had a negative net margin of 33.02% and a negative return on equity of 292.94%. On average, analysts expect that AxoGen will post ($0.38) EPS for the current fiscal year.
In related news, CEO Karen L. Zaderej acquired 10,000 shares of the stock in a transaction on Friday, October 7th. The stock was purchased at an average price of $7.50 per share, for a total transaction of $75,000.00. Following the transaction, the chief executive officer now owns 242,147 shares of the company’s stock, valued at approximately $1,816,102.50. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Amy Mcbride Wendell acquired 13,333 shares of the stock in a transaction on Friday, October 7th. The stock was bought at an average price of $7.50 per share, with a total value of $99,997.50. Following the transaction, the director now directly owns 13,333 shares in the company, valued at approximately $99,997.50. The disclosure for this purchase can be found here. 9.33% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of AXGN. Waddell & Reed Financial Inc. bought a new stake in AxoGen during the second quarter valued at $1,371,000. State Street Corp acquired a new stake in shares of AxoGen during the second quarter valued at approximately $1,885,000. Rhumbline Advisers acquired a new stake in shares of AxoGen during the second quarter valued at approximately $132,000. Teachers Advisors Inc. acquired a new stake in shares of AxoGen during the second quarter valued at approximately $267,000. Finally, TFS Capital LLC acquired a new stake in shares of AxoGen during the second quarter valued at approximately $113,000. Hedge funds and other institutional investors own 52.42% of the company’s stock.